CEPT Inhibitors Finally Show Potential With Obicetrapib

After many setbacks, the potential for CETP inhibition to significantly improve cholesterol levels and target attainment has been shown with obicetrapib in the ROSE trial.
Medscape Medical News

source https://www.medscape.com/viewarticle/974786?src=rss

Comments

Popular posts from this blog

Student Nurses Who Refuse Vaccination Struggle to Complete Degrees

The Clinical Characteristics of Fractures in Pediatric Patients Exposed to Proton Pump Inhibitors